{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:25:40Z","timestamp":1789647940782,"version":"4.0.0"},"reference-count":211,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejphar.2019.172429","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T01:58:54Z","timestamp":1559527134000},"page":"172429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Interventions to chronic prostatitis\/Chronic pelvic pain syndrome treatment. Where are we standing and what's next?"],"prefix":"10.1016","volume":"857","author":[{"given":"Madanraj","family":"Appiya Santharam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zaeem","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puregmaa","family":"Khongorzul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Muhammad","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais Ullah","family":"Ihsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172429_bib1","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1110\/ps.035402.108","article-title":"Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors","volume":"17","author":"Abdiche","year":"2008","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejphar.2019.172429_bib2","series-title":"Pregabalin for Chronic Prostatitis. The Cochrane Database of Systematic Reviews","author":"Aboumarzouk","year":"2012"},{"key":"10.1016\/j.ejphar.2019.172429_bib3","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/nau.23225","article-title":"Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin?","volume":"36","author":"Agarwal","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2019.172429_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.urology.2011.02.065","article-title":"Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms","volume":"78","author":"Akduman","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-141-8-200410190-00005","article-title":"Ciprofloxacin or tamsulosin in men with chronic prostatitis\/chronic pelvic pain syndrome: a randomized, double-blind trial","volume":"141","author":"Alexander","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2019.172429_bib6","doi-asserted-by":"crossref","first-page":"R415","DOI":"10.1152\/ajpregu.00147.2012","article-title":"A novel murine model of chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS) induced by immunization with a spermine binding protein (p25) peptide","volume":"304","author":"Altuntas","year":"2013","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2019.172429_bib7","series-title":"Chronic Prostatitis\/Chronic Pelvic Pain as a Psycho-Neuromuscular Disorder-A Meta-Analysis. Urology","author":"Anderson","year":"2018"},{"key":"10.1016\/j.ejphar.2019.172429_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ncpuro0836","article-title":"Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system","volume":"4","author":"Andersson","year":"2007","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/nau.20999","article-title":"Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action","volume":"30","author":"Andersson","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2019.172429_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jama.2010.1913","article-title":"Management of chronic prostatitis\/chronic pelvic pain syndrome: a systematic review and network meta-analysis","volume":"305","author":"Anothaisintawee","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2019.172429_bib11","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1097\/00002508-200211001-00010","article-title":"A focused review on the use of botulinum toxins for neuropathic pain","volume":"18","author":"Argoff","year":"2002","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ejphar.2019.172429_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0149-2918(03)90011-7","article-title":"Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials","volume":"25","author":"Backonja","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2019.172429_bib13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1469-0691.2012.03807.x","article-title":"Relentless increase of resistance to fluoroquinolones and expanded-spectrum cephalosporins in Escherichia coli: 20 years of surveillance in resource-limited settings from Latin America","volume":"19","author":"Bartoloni","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejphar.2019.172429_bib14","first-page":"395","article-title":"[Male circumcision is an effective \"surgical vaccine\" for HIV prevention and reproductive health]","volume":"15","author":"Ben","year":"2009","journal-title":"Zhonghua nan ke xue = Natl. J. Androl."},{"key":"10.1016\/j.ejphar.2019.172429_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1756287218808677","article-title":"Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis\/chronic pelvic pain syndrome","volume":"10","author":"Benelli","year":"2018","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/pros.23252","article-title":"Chronic pelvic pain development and prostate inflammation in strains of mice with different susceptibility to experimental autoimmune prostatitis","volume":"77","author":"Breser","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172429_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fimmu.2017.00898","article-title":"Immunological mechanisms underlying chronic pelvic pain and prostate inflammation in chronic pelvic pain syndrome","volume":"8","author":"Breser","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00120-007-1384-8","article-title":"[Intraprostatic botulinum toxin A injection in chronic prostatitis and chronic pelvic pain syndrome (CP\/CPPS)]","volume":"46","author":"Bschleipfer","year":"2007","journal-title":"Urol. Ausg. A"},{"key":"10.1016\/j.ejphar.2019.172429_bib19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/gt.2008.10","article-title":"IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis","volume":"15","author":"Butti","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2019.172429_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4081\/aiua.2013.3.109","article-title":"Comparison of tamsulosin vs tamsulosin\/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis","volume":"85","author":"Cantoro","year":"2013","journal-title":"Arch. Ital. Urol. Androl. : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172429_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/fcp.12438","article-title":"A nanoparticle-coupled T2 peptide induces immune tolerance and ameliorates chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS) in mice model","volume":"33","author":"Cao","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172429_bib23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0022-5347(05)63960-2","article-title":"Terazosin therapy for chronic prostatitis\/chronic pelvic pain syndrome: a randomized, placebo controlled trial","volume":"169","author":"Cheah","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00345-010-0537-3","article-title":"Effects of a 6-month course of tamsulosin for chronic prostatitis\/chronic pelvic pain syndrome: a multicenter, randomized trial","volume":"29","author":"Chen","year":"2011","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib25","series-title":"Novel Treatment of Experimental Autoimmune Prostatitis by Nanoparticle-Conjugated Autoantigen Peptide T2. Inflammation","author":"Cheng","year":"2019"},{"key":"10.1016\/j.ejphar.2019.172429_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00044011-200929030-00006","article-title":"Pregabalin in the treatment of chronic pain: an overview","volume":"29","author":"Chiechio","year":"2009","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejphar.2019.172429_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/bja\/ael344","article-title":"Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers","volume":"98","author":"Chizh","year":"2007","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejphar.2019.172429_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jiac.2013.07.010","article-title":"Clinical efficacy of roxithromycin in men with chronic prostatitis\/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial","volume":"20","author":"Choe","year":"2014","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.ejphar.2019.172429_bib29","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.juro.2006.07.127","article-title":"The application of botulinum toxin in the prostate","volume":"176","author":"Chuang","year":"2006","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2006.11.037","article-title":"Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A","volume":"51","author":"Chuang","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.juro.2007.07.120","article-title":"Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat","volume":"180","author":"Chuang","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib32","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1128\/AAC.46.7.2077-2086.2002","article-title":"Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method","volume":"46","author":"Ciftcioglu","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172429_bib33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.juro.2007.05.140","article-title":"Prevalence of and risk factors for prostatitis: population based assessment using physician assigned diagnoses","volume":"178","author":"Clemens","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin A reduces formalin-induced pain","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2019.172429_bib35","first-page":"63","article-title":"Management of men diagnosed with chronic prostatitis\/chronic pelvic pain syndrome who have failed traditional management","volume":"9","author":"Curtis Nickel","year":"2007","journal-title":"Rev. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.urology.2003.08.006","article-title":"Role of mepartricin in category III chronic nonbacterial prostatitis\/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial","volume":"63","author":"De Rose","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.urology.2003.08.006","article-title":"Role of mepartricin in category III chronic nonbacterial prostatitis\/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial","volume":"63","author":"De Rose","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib38","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/j.1600-6143.2009.02755.x","article-title":"Mast cell degranulation breaks peripheral tolerance","volume":"9","author":"de Vries","year":"2009","journal-title":"Am. J. Transplant. :"},{"key":"10.1016\/j.ejphar.2019.172429_bib39","first-page":"88","article-title":"Chronic prostatitis developing due to candida infection: a case diagnosed 20 years later and review of up-to-date literature","volume":"20","author":"Demirci","year":"2018","journal-title":"Urol. Case Rep."},{"key":"10.1016\/j.ejphar.2019.172429_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.urology.2007.09.025","article-title":"Adrenocortical hormone abnormalities in men with chronic prostatitis\/chronic pelvic pain syndrome","volume":"71","author":"Dimitrakov","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib41","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.5489\/cuaj.5325","article-title":"Management of chronic prostatitis\/chronic pelvic pain syndrome","volume":"12","author":"Doiron","year":"2018","journal-title":"Can. Urol. Assoc. J. = Journal de l'Association des urologues du Canada"},{"key":"10.1016\/j.ejphar.2019.172429_bib42","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.5489\/cuaj.5325","article-title":"Management of chronic prostatitis\/chronic pelvic pain syndrome","volume":"12","author":"Doiron","year":"2018","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.ejphar.2019.172429_bib43","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/AAC.44.8.2046-2051.2000","article-title":"A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin","volume":"44","author":"Drusano","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172429_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2019.172429_bib45","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00002508-199409000-00008","article-title":"Psychological problems in chronic prostatitis patients with pain","volume":"10","author":"Egan","year":"1994","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ejphar.2019.172429_bib46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/mt.2009.42","article-title":"Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen","volume":"17","author":"Eixarch","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2019.172429_bib47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.aju.2015.01.001","article-title":"Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: the transurethral vs. transrectal approach","volume":"13","author":"El-enen","year":"2015","journal-title":"Arab. J. of Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib48","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2019.172429_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2005.07.035","article-title":"Effects of pollen extract preparation Prostat\/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis\/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study","volume":"67","author":"Elist","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib50","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.juro.2010.12.088","article-title":"Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis","volume":"185","author":"Evans","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bju.12951","article-title":"Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis\/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study","volume":"116","author":"Falahatkar","year":"2015","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.172429_bib52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.eururo.2004.07.030","article-title":"EAU guidelines on chronic pelvic pain","volume":"46","author":"Fall","year":"2004","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2006.08.1106","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome and male interstitial cystitis: enigmas and opportunities","volume":"69","author":"Forrest","year":"2007","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ejphar.2019.172429_bib54","article-title":"Non-pharmacological interventions for treating chronic prostatitis\/chronic pelvic pain syndrome: a Cochrane systematic review","volume":"2018","author":"Franco","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ejphar.2019.172429_bib55","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","article-title":"Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"70","author":"Gacci","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0092-8674(04)00340-X","article-title":"Driven to autoimmunity: the nod mouse","volume":"117","author":"Gallegos","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2019.172429_bib57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/cs0990405","article-title":"Effect of ciprofloxacin on the activation of the transcription factors nuclear factor kappaB, activator protein-1 and nuclear factor-interleukin-6, and interleukin-6 and interleukin-8 mRNA expression in a human endothelial cell line","volume":"99","author":"Galley","year":"2000","journal-title":"Clin. Sci."},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2019.172429_bib58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1464-410X.2008.07493.x","article-title":"The concept of neurogenic inflammation","volume":"101","author":"Geppetti","year":"2008","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.172429_bib59","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.4049\/jimmunol.1004175","article-title":"Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells","volume":"187","author":"Getts","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib60","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/nbt.2434","article-title":"Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis","volume":"30","author":"Getts","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2019.172429_bib61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2015.05.007","article-title":"Harnessing nanoparticles for immune modulation","volume":"36","author":"Getts","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.urology.2013.09.024","article-title":"The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis\/chronic pelvic pain syndrome","volume":"83","author":"Giannantoni","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tice.2014.08.001","article-title":"Effect of chronic Sildenafil treatment on the prostate of C57Bl\/6 mice","volume":"46","author":"Gomes","year":"2014","journal-title":"Tissue Cell"},{"key":"10.1016\/j.ejphar.2019.172429_bib64","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/030079908X301866","article-title":"An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast","volume":"24","author":"Gottlieb","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2019.172429_bib65","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00000542-200412000-00021","article-title":"Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia","volume":"101","author":"Gottrup","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejphar.2019.172429_bib66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11934-010-0118-4","article-title":"A review of botulinum toxin use for chronic pelvic pain syndrome","volume":"11","author":"Gottsch","year":"2010","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.ejphar.2019.172429_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/00365599.2010.529820","article-title":"A pilot study of botulinum toxin A for male chronic pelvic pain syndrome","volume":"45","author":"Gottsch","year":"2011","journal-title":"Scand. J. Urol. Nephrol."},{"key":"10.1016\/j.ejphar.2019.172429_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mehy.2006.11.040","article-title":"Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms","volume":"69","author":"Grimsley","year":"2007","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejphar.2019.172429_bib69","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1017504830834","article-title":"Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index","volume":"32","author":"Gul","year":"2001","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.ejphar.2019.172429_bib70","first-page":"1088","article-title":"[Levels of cytokines and heat-shock protein 70 in the seminal plasma of patients with chronic bacterial prostatitis and chronic prostatitis\/chronic pelvic pain syndrome]","volume":"18","author":"Guo","year":"2012","journal-title":"Zhonghua nan ke xue = Natl. J. Androl."},{"key":"10.1016\/j.ejphar.2019.172429_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.med.57.011205.135654","article-title":"Prostatitis\/chronic pelvic pain syndrome","volume":"57","author":"Habermacher","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2019.172429_bib72","first-page":"582","article-title":"[Update of the usefulness of alpha-blockers in the treatment of different urologic pathologies]","volume":"139","author":"Hernandez Fernandez","year":"2012","journal-title":"Med. Cl\u00ednica"},{"key":"10.1016\/j.ejphar.2019.172429_bib73","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-5347(05)67987-6","article-title":"Evaluation of the bacterial flora of the prostate using a 16S rRNA gene based polymerase chain reaction","volume":"163","author":"Hochreiter","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib74","first-page":"2031","article-title":"An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans","volume":"119","author":"Hou","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2019.172429_bib75","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/aja.2012.30","article-title":"Characterisation of the bacterial community in expressed prostatic secretions from patients with chronic prostatitis\/chronic pelvic pain syndrome and infertile men: a preliminary investigation","volume":"14","author":"Hou","year":"2012","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.ejphar.2019.172429_bib76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.biopha.2017.05.004","article-title":"Establishment of a rat model of chronic Prostatitis\/Chronic Pelvic Pain Syndrome (CP\/CPPS) induced by immunization with a novel peptide T2","volume":"91","author":"Ihsan","year":"2017","journal-title":"Biomed. Pharmacother. = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejphar.2019.172429_bib77","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.biopha.2018.06.139","article-title":"Role of oxidative stress in pathology of chronic prostatitis\/chronic pelvic pain syndrome and male infertility and antioxidants function in ameliorating oxidative stress","volume":"106","author":"Ihsan","year":"2018","journal-title":"Biomed. Pharmacother. = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejphar.2019.172429_bib78","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000112606","article-title":"Treatment for chronic prostatitis\/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination","volume":"80","author":"Jeong","year":"2008","journal-title":"Urol. Int."},{"key":"10.1016\/j.ejphar.2019.172429_bib79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrurol.2015.193","article-title":"Current and potential urological applications of botulinum toxin A","volume":"12","author":"Jiang","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jri.2016.09.004","article-title":"Association of anti-sperm antibodies with chronic prostatitis: a systematic review and meta-analysis","volume":"118","author":"Jiang","year":"2016","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib81","first-page":"337","article-title":"Inhibitory action of roxithromycin on histamine release and prostaglandin D2 production from beta-defensin 2-stimulated mast cells","volume":"23","author":"Kase","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2019.172429_bib82","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.biopha.2017.08.016","article-title":"Comprehensive overview of prostatitis","volume":"94","author":"Khan","year":"2017","journal-title":"Biomed. Pharmacother. = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejphar.2019.172429_bib83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.imlet.2017.05.008","article-title":"A novel mouse model of chronic prostatitis\/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant","volume":"187","author":"Khan","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejphar.2019.172429_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14777\/uti.2018.13.1.1","article-title":"The effect of alpha-blockers monotherapy vs. Combination antibiotic therapy on symptom alleviation in patients with chronic prostatitis\/chronic pelvic pain syndrome","volume":"13","author":"Kim","year":"2018","journal-title":"Urogenit.Tract Infect."},{"key":"10.1016\/j.ejphar.2019.172429_bib85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5534\/wjmh.2014.32.3.145","article-title":"The efficacy of mirodenafil for chronic prostatitis\/chronic pelvic pain syndrome in middle-aged males","volume":"32","author":"Kong do","year":"2014","journal-title":"J. World Men's Health"},{"key":"10.1016\/j.ejphar.2019.172429_bib86","first-page":"2280","article-title":"Electrophysiological identification of central sensitization in patients with chronic prostatitis","volume":"12","author":"Korkmaz","year":"2015","journal-title":"Urol. J."},{"key":"10.1016\/j.ejphar.2019.172429_bib87","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/S0022-5347(05)65041-0","article-title":"Bacteria in the chronic prostatitis-chronic pelvic pain syndrome: molecular approaches to critical research questions","volume":"167","author":"Krieger","year":"2002","journal-title":"J. Urol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2019.172429_bib88","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ijantimicag.2007.08.028","article-title":"Epidemiology of prostatitis","volume":"31","author":"Krieger","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2019.172429_bib89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10156-008-0593-4","article-title":"Gatifloxacin treatment for chronic prostatitis: a prospective multicenter clinical trial","volume":"14","author":"Kunishima","year":"2008","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.ejphar.2019.172429_bib90","first-page":"1157","article-title":"Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain","volume":"78","author":"Kurita","year":"2018"},{"key":"10.1016\/j.ejphar.2019.172429_bib91","volume":"vol. 21","author":"Lee","year":"2016"},{"key":"10.1016\/j.ejphar.2019.172429_bib92","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0090-4295(98)00540-8","article-title":"Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study","volume":"53","author":"Leskinen","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-018-0684-3","article-title":"Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2019.172429_bib94","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.biopha.2017.04.055","article-title":"Therapeutic effect of melittin on a rat model of chronic prostatitis induced by Complete Freund's Adjuvant","volume":"90","author":"Lin","year":"2017","journal-title":"Biomed. Pharmacother. = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejphar.2019.172429_bib95","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-5347(05)68562-X","article-title":"The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network","volume":"162","author":"Litwin","year":"1999","journal-title":"J. Urol."},{"issue":"14","key":"10.1016\/j.ejphar.2019.172429_bib96","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/pros.23684","article-title":"Identification and preliminary study of immunogens involved in autoimmune prostatitis in human males","volume":"78","author":"Lu","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172429_bib97","doi-asserted-by":"crossref","first-page":"14527","DOI":"10.1073\/pnas.0805204105","article-title":"ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms","volume":"105","author":"Luo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2019.172429_bib98","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S1081-1206(10)61326-9","article-title":"Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules","volume":"94","author":"Maeba","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib99","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.eururo.2015.08.061","article-title":"Contemporary management of chronic prostatitis\/chronic pelvic pain syndrome","volume":"69","author":"Magistro","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/aja.2011.36","article-title":"Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction","volume":"13","author":"Magri","year":"2011","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.ejphar.2019.172429_bib101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib102","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(05)79580-5","article-title":"Relief by botulinum toxin of voiding dysfunction due to prostatitis","volume":"352","author":"Maria","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2019.172429_bib103","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1757-5672.2012.00150.x","article-title":"Apremilast in the treatment of chronic prostatitis\/chronic pelvic pain syndrome: a pilot study","volume":"4","author":"Mc","year":"2012","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"10.1016\/j.ejphar.2019.172429_bib104","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0304-3959(96)03140-5","article-title":"A systematic review of antidepressants in neuropathic pain","volume":"68","author":"McQuay","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2019.172429_bib105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-5347(05)65399-2","article-title":"The chronic prostatitis-chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements","volume":"167","author":"Mehik","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib106","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0090-4295(03)00466-7","article-title":"Alfuzosin treatment for chronic prostatitis\/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study","volume":"62","author":"Mehik","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib107","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0090-4295(01)01597-7","article-title":"Nerve growth factor and chronic prostatitis\/chronic pelvic pain syndrome","volume":"59","author":"Miller","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib108","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/pros.22584","article-title":"Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit","volume":"73","author":"Morelli","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172429_bib109","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/14656561003709748","article-title":"Pharmacotherapy strategies in chronic prostatitis\/chronic pelvic pain syndrome management","volume":"11","author":"Murphy","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2019.172429_bib110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrurol.2014.63","article-title":"Immune mediators of chronic pelvic pain syndrome","volume":"11","author":"Murphy","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib111","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/pros.23721","article-title":"Role of gram-positive bacteria in chronic pelvic pain syndrome (CPPS)","volume":"79","author":"Murphy","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172429_bib112","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/pros.23721","article-title":"Role of gram-positive bacteria in chronic pelvic pain syndrome (CPPS)","volume":"79","author":"Murphy","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172429_bib113","first-page":"31","article-title":"[Naiz (nimesulid) in combined treatment of patients with chronic non-bacterial prostatitis with chronic pelvic pain syndrome]","author":"Neimark","year":"2004","journal-title":"Urologiia"},{"key":"10.1016\/j.ejphar.2019.172429_bib114","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1464-410X.2004.05148.x","article-title":"The three as of chronic prostatitis therapy: antibiotics, alpha-blockers and anti-inflammatories. What is the evidence?","volume":"94","author":"Nickel","year":"2004","journal-title":"BJU Int."},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2019.172429_bib115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1464-410X.2008.07496.x","article-title":"Role of alpha1-blockers in chronic prostatitis syndromes","volume":"101","author":"Nickel","year":"2008","journal-title":"BJU Int."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2019.172429_bib116","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.ijantimicag.2007.07.028","article-title":"Treatment of chronic prostatitis\/chronic pelvic pain syndrome","volume":"31","author":"Nickel","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2019.172429_bib117","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.juro.2009.04.052","article-title":"Chronic prostatitis\/chronic pelvic pain: the syndrome","volume":"182","author":"Nickel","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib118","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4111\/icu.2017.58.3.149","article-title":"Is chronic prostatitis\/chronic pelvic pain syndrome an infectious disease of the prostate?","volume":"58","author":"Nickel","year":"2017","journal-title":"Investig.Clin.Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib119","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1464-410X.2010.09701.x","article-title":"Phenotypic approach to the management of the chronic prostatitis\/chronic pelvic pain syndrome","volume":"106","author":"Nickel","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.172429_bib120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0090-4295(00)00685-3","article-title":"Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial","volume":"56","author":"Nickel","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib121","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0022-5347(05)66344-6","article-title":"Predictors of patient response to antibiotic therapy for the chronic prostatitis\/chronic pelvic pain syndrome: a prospective multicenter clinical trial","volume":"165","author":"Nickel","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib122","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0090-4295(03)00583-1","article-title":"Levofloxacin for chronic prostatitis\/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial","volume":"62","author":"Nickel","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib123","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/01.ju.0000054983.45096.16","article-title":"A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis","volume":"169","author":"Nickel","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib124","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1464-410X.2003.04766.x","article-title":"A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis)","volume":"93","author":"Nickel","year":"2004","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.172429_bib125","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/01.ju.0000117811.40279.19","article-title":"Treatment of chronic prostatitis\/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial","volume":"171","author":"Nickel","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib126","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/01.ju.0000159198.83103.01","article-title":"Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study","volume":"173","author":"Nickel","year":"2005","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib127","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1056\/NEJMoa0803240","article-title":"Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome","volume":"359","author":"Nickel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2019.172429_bib128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00345-008-0235-6","article-title":"Development of an evidence-based cognitive behavioral treatment program for men with chronic prostatitis\/chronic pelvic pain syndrome","volume":"26","author":"Nickel","year":"2008","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.juro.2011.03.028","article-title":"Silodosin for men with chronic prostatitis\/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study","volume":"186","author":"Nickel","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib130","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2011.05.071","article-title":"Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study","volume":"186","author":"Nickel","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib131","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.urology.2012.07.035","article-title":"Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis\/chronic pelvic pain syndrome","volume":"80","author":"Nickel","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib132","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00345-013-1062-y","article-title":"Management of chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS): the studies, the evidence, and the impact","volume":"31","author":"Nickel","year":"2013","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib133","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40261-016-0423-x","article-title":"Pregabalin for neuropathic pain: why benefits could Be expected for multiple pain conditions","volume":"36","author":"Ogawa","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejphar.2019.172429_bib134","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/pros.23514","article-title":"Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis","volume":"78","author":"Okamoto","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172429_bib135","first-page":"797031","article-title":"Antidepressant drugs for chronic urological pelvic pain: an evidence-based review","author":"Papandreou","year":"2009","journal-title":"Adv. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(12)60277-2","article-title":"280 the efficacy of tadalafil for chronic prostatitis\/chronic pelvic pain syndrome in young and middle aged patients","volume":"11","author":"Park","year":"2012","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.ejphar.2019.172429_bib137","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S1569-9056(17)30324-X","article-title":"Efficacy of tadalafil for treating chronic prostatitis\/chronic pelvic pain syndrome in patients without erectile dysfunction","volume":"16","author":"Park","year":"2017","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.ejphar.2019.172429_bib138","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12950-015-0099-7","article-title":"The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review","volume":"12","author":"Peixoto","year":"2015","journal-title":"J. Inflamm."},{"key":"10.1016\/j.ejphar.2019.172429_bib139","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4049\/jimmunol.179.3.1559","article-title":"Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse","volume":"179","author":"Penna","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.eururo.2006.07.016","article-title":"Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis\/chronic pelvic pain syndrome and benign prostatic hyperplasia","volume":"51","author":"Penna","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib141","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2680.2000.00195.x","article-title":"The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies","volume":"20","author":"Pennefather","year":"2000","journal-title":"J. Auton. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172429_bib142","series-title":"Anti-Inflammatory Effect of Dialyzable Leukocyte Extract in Autoimmune Prostatitis: Evaluation in Animal Model","first-page":"1832853","author":"Perez-Alvarado","year":"2017"},{"key":"10.1016\/j.ejphar.2019.172429_bib143","series-title":"Antimicrobial therapy for chronic bacterial prostatitis","author":"Perletti","year":"2013"},{"key":"10.1016\/j.ejphar.2019.172429_bib144","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/pcan.2016.8","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome: a review of evaluation and therapy","volume":"19","author":"Polackwich","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejphar.2019.172429_bib146","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2165\/00002512-200320150-00004","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment","volume":"20","author":"Pontari","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejphar.2019.172429_bib147","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.ju.0000136002.76898.04","article-title":"Mechanisms in prostatitis\/chronic pelvic pain syndrome","volume":"172","author":"Pontari","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib148","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.juro.2008.03.139","article-title":"Mechanisms in prostatitis\/chronic pelvic pain syndrome","volume":"179","author":"Pontari","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib149","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1464-410X.2005.05684.x","article-title":"A case-control study of risk factors in men with chronic pelvic pain syndrome","volume":"96","author":"Pontari","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.172429_bib150","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinternmed.2010.319","article-title":"Pregabalin for the treatment of men with chronic prostatitis\/chronic pelvic pain syndrome: a randomized controlled trial","volume":"170","author":"Pontari","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2019.172429_bib151","first-page":"345","article-title":"The microbiome in prostate inflammation and prostate cancer","volume":"21","author":"Porter","year":"2018"},{"key":"10.1016\/j.ejphar.2019.172429_bib152","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11136-005-1317-1","article-title":"Responsiveness of the national Institutes of health chronic prostatitis symptom index (NIH-CPSI)","volume":"15","author":"Propert","year":"2006","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ejphar.2019.172429_bib153","first-page":"509","article-title":"Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis\/chronic pelvic pain syndrome","volume":"116","author":"Rees","year":"2015","journal-title":"Consens. Guidel."},{"key":"10.1016\/j.ejphar.2019.172429_bib154","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jpsychores.2014.09.012","article-title":"Assessing psychological factors, social aspects and psychiatric co-morbidity associated with Chronic Prostatitis\/Chronic Pelvic Pain Syndrome (CP\/CPPS) in men -- a systematic review","volume":"77","author":"Riegel","year":"2014","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.ejphar.2019.172429_bib155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/clim.2002.5281","article-title":"Prostatein or steroid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP) in NOD mice","volume":"105","author":"Rivero","year":"2002","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejphar.2019.172429_bib156","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.autrev.2013.07.002","article-title":"CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance","volume":"12","author":"Romo-Tena","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2019.172429_bib157","doi-asserted-by":"crossref","first-page":"R1268","DOI":"10.1152\/ajpregu.00836.2007","article-title":"Experimental autoimmune prostatitis induces chronic pelvic pain","volume":"294","author":"Rudick","year":"2008","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2019.172429_bib158","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.toxicon.2018.01.017","article-title":"Botulinum toxin treatment of pain syndromes -an evidence based review","volume":"147","author":"Safarpour","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.ejphar.2019.172429_bib159","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00210-016-1325-4","article-title":"The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate","volume":"390","author":"Said","year":"2017","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172429_bib160","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/07853890802698842","article-title":"Challenges in monoclonal antibody-based therapies","volume":"41","author":"Samaranayake","year":"2009","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejphar.2019.172429_bib161","author":"Sandhu","year":"2017"},{"key":"10.1016\/j.ejphar.2019.172429_bib162","first-page":"21","article-title":"Antidepressants as analgesics: an overview of central and peripheral mechanisms of action","volume":"26","author":"Sawynok","year":"2001","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.ejphar.2019.172429_bib163","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.urology.2003.11.002","article-title":"Etiology and management of chronic pelvic pain syndrome in men","volume":"63","author":"Schaeffer","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib164","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMcp060423","article-title":"Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome","volume":"355","author":"Schaeffer","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2019.172429_bib165","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.ijantimicag.2007.08.027","article-title":"Epidemiology and evaluation of chronic pelvic pain syndrome in men","volume":"31","author":"Schaeffer","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2019.172429_bib166","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases","volume":"2","author":"Schett","year":"2010","journal-title":"Ther. Adv. Muscoskel. Dis."},{"key":"10.1016\/j.ejphar.2019.172429_bib167","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00345-003-0338-z","article-title":"Experience with different questionnaires in the management of patients with CP\/CPPS: GPSS, IPSS and NIH-CPSI","volume":"21","author":"Schneider","year":"2003","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib168","first-page":"751","volume":"vol. 48","author":"Serra","year":"2018"},{"key":"10.1016\/j.ejphar.2019.172429_bib169","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2005-08-3088","article-title":"Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells","volume":"107","author":"Setiady","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2019.172429_bib170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrurol.2017.167","article-title":"The inflammatory microenvironment and microbiome in prostate cancer development","volume":"15","author":"Sfanos","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib171","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ucl.2011.05.003","article-title":"Quercetin for chronic prostatitis\/chronic pelvic pain syndrome","volume":"38","author":"Shoskes","year":"2011","journal-title":"Urol. Clin."},{"key":"10.1016\/j.ejphar.2019.172429_bib172","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0090-4295(99)00358-1","article-title":"Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial","volume":"54","author":"Shoskes","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib173","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-5347(05)64916-6","article-title":"Cytokine polymorphisms in men with chronic prostatitis\/chronic pelvic pain syndrome: association with diagnosis and treatment response","volume":"168","author":"Shoskes","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib174","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/01.ju.0000150062.60633.b2","article-title":"Anti-nanobacterial therapy for men with chronic prostatitis\/chronic pelvic pain syndrome and prostatic stones: preliminary experience","volume":"173","author":"Shoskes","year":"2005","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib175","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.juro.2007.09.088","article-title":"Muscle tenderness in men with chronic prostatitis\/chronic pelvic pain syndrome: the chronic prostatitis cohort study","volume":"179","author":"Shoskes","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib176","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2008.42","article-title":"Clinical phenotyping in chronic prostatitis\/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes","volume":"12","author":"Shoskes","year":"2009","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejphar.2019.172429_bib177","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.autrev.2011.11.017","article-title":"Genes, tolerance and systemic autoimmunity","volume":"11","author":"Singh","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2019.172429_bib178","first-page":"833","article-title":"Review of duloxetine in the management of diabetic peripheral neuropathic pain","volume":"3","author":"Smith","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejphar.2019.172429_bib179","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11934-002-0081-9","article-title":"Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction","volume":"3","author":"Smith","year":"2002","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.ejphar.2019.172429_bib180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0090-6980(96)00005-6","article-title":"The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4","volume":"51","author":"Spaziani","year":"1996","journal-title":"Prostaglandins"},{"key":"10.1016\/j.ejphar.2019.172429_bib181","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.urology.2008.04.005","article-title":"Effect of antibiotic therapy on interleukin-6 in fresh semen and postmasturbation urine samples of patients with chronic prostatitis\/chronic pelvic pain syndrome","volume":"72","author":"Stancik","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib182","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrurol.2010.4","article-title":"New treatments for chronic prostatitis\/chronic pelvic pain syndrome","volume":"7","author":"Strauss","year":"2010","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib183","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1464-410X.2012.11088.x","article-title":"alpha-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis\/chronic pelvic pain syndrome","volume":"110","author":"Thakkinstian","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2019.172429_bib184","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4081\/aiua.2018.1.34","article-title":"Injection therapy for chronic prostatitis: a retrospective analysis of 77 cases","volume":"90","author":"Toth","year":"2018","journal-title":"Arch. Ital. Urol. Androl. : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica"},{"key":"10.1016\/j.ejphar.2019.172429_bib185","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5489\/cuaj.690","article-title":"A feasibility trial of a cognitive-behavioural symptom management program for chronic pelvic pain for men with refractory chronic prostatitis\/chronic pelvic pain syndrome","volume":"5","author":"Tripp","year":"2011","journal-title":"Can. Urol. Assoc. J. = Journal de l'Association des urologues du Canada"},{"key":"10.1016\/j.ejphar.2019.172429_bib186","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.eururo.2006.09.036","article-title":"A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS)","volume":"51","author":"Tugcu","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib187","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2005.12.050","article-title":"Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate","volume":"49","author":"Uckert","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib188","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2009.05.046","article-title":"A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study","volume":"56","author":"Wagenlehner","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib189","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11255-015-1147-1","article-title":"A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis\/chronic pelvic pain syndrome","volume":"48","author":"Wang","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.ejphar.2019.172429_bib190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/iju.13706","article-title":"Psychotherapy combined with drug therapy in patients with category III chronic prostatitis\/chronic pelvic pain syndrome: a randomized controlled trial","volume":"25","author":"Wang","year":"2018","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib191","first-page":"2158","article-title":"Fluoxetine ameliorates symptoms of refractory chronic prostatitis\/chronic pelvic pain syndrome","volume":"124","author":"Xia","year":"2011","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejphar.2019.172429_bib192","unstructured":"Yamaguchi, H., Kurita, M., Okamoto, K., Kotera, T., Oka, M., Voiding Behavior and Chronic Pelvic Pain in Two Types of Rat Nonbacterial Prostatitis Models: Attenuation of Chronic Pelvic Pain by Repeated Administration of Tadalafil. The Prostate 0."},{"key":"10.1016\/j.ejphar.2019.172429_bib193","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11934-005-0026-1","article-title":"Saw palmetto and finasteride in the treatment of category-III prostatitis\/chronic pelvic pain syndrome","volume":"6","author":"Yang","year":"2005","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.ejphar.2019.172429_bib194","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/01.ju.0000082710.47402.03","article-title":"Pain sensitization in male chronic pelvic pain syndrome: why are symptoms so difficult to treat?","volume":"170","author":"Yang","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib195","first-page":"237","article-title":"[Corticoid combined with an antibiotic for chronic nonbacterial prostatitis]","volume":"15","author":"Yang","year":"2009","journal-title":"Zhonghua nan ke xue = Natl. J. Androl."},{"key":"10.1016\/j.ejphar.2019.172429_bib196","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.108.139501","article-title":"Fispemifene [<em>Z<\/em>-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis","volume":"327","author":"Yatkin","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.172429_bib197","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.108.139501","article-title":"Fispemifene [Z-2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis","volume":"327","author":"Yatkin","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.172429_bib198","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/147323000803600205","article-title":"Tamsulosin treatment of chronic non-bacterial prostatitis","volume":"36","author":"Ye","year":"2008","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ejphar.2019.172429_bib199","doi-asserted-by":"crossref","DOI":"10.1177\/1744806917740233","article-title":"Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications","volume":"13","author":"Yeh","year":"2017","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejphar.2019.172429_bib200","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/pros.23447","article-title":"Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue","volume":"78","author":"Yellepeddi","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172429_bib201","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.juro.2007.01.144","article-title":"Autonomic nervous system changes in men with chronic pelvic pain syndrome","volume":"177","author":"Yilmaz","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib202","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","article-title":"Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial","volume":"72","author":"Yuan","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2019.172429_bib203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11934-018-0841-9","article-title":"Management of chronic prostatitis (CP)","volume":"19","author":"Zaidi","year":"2018","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.ejphar.2019.172429_bib204","first-page":"278","article-title":"[Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis]","volume":"10","author":"Zeng","year":"2004","journal-title":"Zhonghua nan ke xue = Natl. J. Androl."},{"key":"10.1016\/j.ejphar.2019.172429_bib205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000020314","article-title":"Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain?","volume":"38","author":"Zermann","year":"2000","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib206","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxicon.2017.08.017","article-title":"Botulinum toxin to treat pelvic pain","volume":"147","author":"Zhang","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.ejphar.2019.172429_bib207","article-title":"Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis\/chronic pelvic pain syndrome: an observational study","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2019.172429_bib208","first-page":"963","article-title":"Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA)","volume":"42","author":"Zhao","year":"2009","journal-title":"Braz. J. Med. Biol. Res. = Revista brasileira de pesquisas medicas e biologicas"},{"key":"10.1016\/j.ejphar.2019.172429_bib209","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4103\/1008-682X.131706","article-title":"Redundant prepuce increases the odds of chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS)","volume":"16","author":"Zhao","year":"2014","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.ejphar.2019.172429_bib210","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00345-014-1350-1","article-title":"Circumcision plus antibiotic, anti-inflammatory, and alpha-blocker therapy for the treatment for chronic prostatitis\/chronic pelvic pain syndrome: a prospective, randomized, multicenter trial","volume":"33","author":"Zhao","year":"2015","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2019.172429_bib211","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.urology.2008.02.041","article-title":"Detection of nanobacteria infection in type III prostatitis","volume":"71","author":"Zhou","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2019.172429_bib212","first-page":"823","article-title":"[Detection of bacterial signal of 16S rRNA gene in prostate tissues obtained by perineal approach from patient with chronic pelvic pain syndrome]","volume":"89","author":"Zhu","year":"2009","journal-title":"Zhonghua Yixue Zazhi"},{"key":"10.1016\/j.ejphar.2019.172429_bib213","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/DMSO.S4719","article-title":"Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine","volume":"3","author":"Zilliox","year":"2010","journal-title":"Diabetes, Metab. Syndrome Obes. Targets Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:26:36Z","timestamp":1757975196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919303802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":211,"alternative-id":["S0014299919303802"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172429","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interventions to chronic prostatitis\/Chronic pelvic pain syndrome treatment. Where are we standing and what's next?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172429"}}